Introduction c-Kit is a receptor tyrosine kinase (RTK), which constitutes a type III RTK subfamily with the receptors for platelet-derived growth factor (PDGF), colony-stimulating factor 1 (CSF-1), and flt-3 ligand. 1,2 The type III RTKs are characterized by an extracellular domain with 5 immunoglobulinlike domains and a cytoplasmic domain consisting of a kinase domain that is interrupted by a kinase insert. c-Kit (KIT) and its ligand stem cell factor (SCF) play an important role in hematopoiesis, melanogenesis, and gametogenesis, 3 as has been clearly shown by loss of function mutations of c-kit gene. In addition, c-kit gene product has been associated with various forms of neoplasms. Activating mutants of KIT, either in the juxtamembrane domain or the catalytic domain, were identified as the cause for transformation of hematopoietic stem cells, mast cells, and gastrointestinal stromal cells. [4][5][6][7][8][9][10] Thus, KIT/SCF has pleiotropic functions such as proliferation, survival, differentiation, and transformation. In this report, we focus on SCF/KITmediated cell migration, which is also a characteristic function of SCF in hematopoietic stem cells and mast cells, [11][12][13] and has critical roles in immunity, metastasis, and development.On ligand stimulation, KIT receptors dimerize, activate its intrinsic tyrosine kinase, and autophosphorylate. The phosphorylated KIT receptor generates binding sites for SH2 domaincontaining proteins, which include proteins of the p21Ras-mitogenactivated protein kinase (MAPK) pathway, 14 the p85 subunit of phosphatidylinositol 3Ј kinase (PI3K), 15 phospholipase C-␥ 1 , the Grb2 adaptor protein, 16 the Src family kinases (SFKs), 17 Cbl, CRKL, 19 SHP1, and SHP2. 20 Those proteins are subsequently activated or phosphorylated and further transduce signaling cascades that lead to various cellular responses. However, little is known about which signaling is essential for SCF-mediated migration. Recently, a few reports indicated that Lyn or p38 MAPK plays an important role, 21,22 but no comprehensive investigation has been done in which the tyrosine residue of KIT is involved in signal transduction, which is required for cell migration. In this study, we have converted all possible tyrosine (Y) residues on KIT cytoplasmic domain to phenylalanine (F) and introduced these YF substitute mutants on 293T cells or murine interleukin 3 (IL-3)-dependent BAF3 cells. We used these cell lines to elucidate signaling cascades that are important for SCF-mediated cell Supported in part by grants from the Japanese Ministry of Education, Culture, Sports, Science and Technology, the Japanese Ministry of Health, Labor and Welfare, and the Japan Society for Promotion of Science.Reprints: Yuzuru Kanakura, Department of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2, Yamada-oka, Suita, Osaka 565-0871, Japan; e-mail: kanakura@bldon.med.osaka-u.ac.jp.The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate thi...
BCR/ABL tyrosine kinase generated from the chromosomal translocation t(9;22) causes chronic myelogenous leukemia and acute lymphoblastic leukemia. To examine the roles of BCR/ABL-activated individual signaling molecules and their cooperation in leukemogenesis, we inducibly expressed a dominant negative (DN) form of Ras, phosphatidylinositol 3-kinase, and STAT5 alone or in combination in p210 BCR/ABL-positive K562 cells. The inducibly expressed DN Ras (N17), STAT5 (694F), and DN phosphatidylinositol 3-kinase (⌬p85) inhibited the growth by 90, 55, and 40%, respectively. During the growth inhibition, the expression of cyclin D2 and cyclin D3 was suppressed by N17, 694F, or ⌬p85; that of cyclin E by N17; and that of cyclin A by ⌬p85. In addition, N17 induced apoptosis in a small proportion of K562, whereas 694F and ⌬p85 were hardly effective. In contrast, coexpression of two DN mutants in any combinations induced severe apoptosis. During these cultures, the expression of Bcl-2 was suppressed by N17, 694F, or ⌬p85, and that of Bcl-XL by N17. Furthermore, although K562 was resistant to interferon-␣-and dexamethasoneinduced apoptosis, disruption of one pathway by N17, 694F, or ⌬p85 sensitized K562 to these reagents. These results suggested that cooperation among these molecules is required for full leukemogenic activities of BCR/ABL.
Tyrosine kinase oncoproteins cause simultaneous activation of multiple intracellular signaling pathways. However, the precise mechanisms by which individual pathways induce oncogenesis are not well understood. We have investigated the roles of individual signaling pathways in v-Src-dependent cell growth and survival by inhibiting one particular pathway. v-Src induced constitutive activation of signal transducers and activators of transcription 3 (STAT3), phosphatidylinositol 3-kinase, and Ras in murine Ba/F3 cells and led to factorindependent proliferation. Dominant-negative mutants of STAT3 (STAT3D) and phosphatidylinositol 3-kinase (⌬p85) inhibited v-Src-dependent growth by ϳ60 and ϳ40%, respectively. Moreover, dominant-negative Ras (N17) induced severe apoptosis, which was accompanied by down-regulation of Bcl-2 and activation of caspase-3. Although cells overexpressing Bcl-2 or caspase-3 inhibitors remained viable even when N17 was expressed, the growth was reduced by ϳ85%. During N17-and STAT3D-induced growth suppression, expression of cyclin D2, cyclin D3, c-myc, and c-fos was suppressed by N17, whereas that of cyclin D2, cyclin E, and c-myc was suppressed by STAT3D. Thus, v-Src-activated Ras and STAT3 are involved in distinct but partly overlapping transcriptional regulation of cell cycle regulatory molecules. These results suggest that the full oncogenic activity of v-Src requires simultaneous activation of multiple signalings, in which Ras is particularly required for survival.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.